Oscillating Positive Expiratory Pressure (OPEP) Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the oscillating positive expiratory pressure (OPEP) devices market size was valued at USD 2.84 billion in 2025 and estimated to grow from USD 2.99 billion in 2026 to reach USD 3.86 billion by 2031, at a CAGR of 5.26% during the forecast period (2026-2031).

This report is Segmented by Product Type (Face Mask PEP Devices, Mouthpiece PEP Devices, and More), Indication (COPD and Asthma, Bronchitis, and More), End-User (Hospital & Clinics, and More), Distribution Channel (Offline Retail and Online Platforms), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Oscillating Positive Expiratory Pressure (OPEP) Devices Market Trends and Insights

Rising Prevalence Of COPD & Asthma

COPD affects 11.7 million insured adults >= 40 years in the United States, creating large-scale, persistent demand for airway-clearance solutions. Higher mortality among Medicare-insured patients underscores the clinical and financial urgency behind earlier, continuous therapy adoption. Aging drives progressive respiratory-muscle weakness that magnifies mucus retention risk and pushes health systems to favor mechanical aids that minimise exacerbations. As payers scrutinise hospital readmission penalties, hospitals increasingly prioritise oscillating positive expiratory pressure (OPEP) devices market products to keep COPD and asthma patients stable at home. Public-health campaigns now highlight airway-clearance adherence as a preventive measure, broadening device familiarity among primary-care physicians and patients alike.

Technological Advancements In Portable, Gravity-Independent OPEP Devices

Gravity-independent engineering removes posture limits that once curtailed bedside and ambulatory use. Trials show T-PEP systems boosting FVC by 10.25% and FEV1 by 7.06% versus baseline, plus lower exacerbation incidence after three months. Battery-powered oscillators automate frequency and amplitude based on real-time airflow sensing, personalising mucus mobilisation while collecting usage analytics for clinicians. Bluetooth-enabled dashboards link into respiratory-management apps, letting providers verify adherence and intervene remotely, a capability that aligns with U.S. remote-physiologic-monitoring CPT codes. Collectively, such innovations reposition devices as data-rich platforms, underpinning a premium tier within the oscillating positive expiratory pressure (OPEP) devices market.

Shortage Of Trained Respiratory Therapists

Many countries face tight labour markets for respiratory therapists, restricting capacity to teach airway-clearance techniques. A U.S. partnership launched in 2024 aims to graduate more professionals in 18 months, yet such programs remain rare and localised. Urban concentration of existing therapists leaves rural COPD clusters underserved, hampering equipment utilisation rates even when devices are supplied. Reimbursement gaps for pulmonary rehabilitation discourage some hospitals from expanding staff rosters, further constraining uptake. Device makers are consequently embedding audiovisual coaching features to guide self-management and offset clinician shortages.

Other drivers and restraints analyzed in the detailed report include:

1. Inclusion In Global GOLD & ERS Clinical Guidelines
2. Rapid Growth Of Home-Based Respiratory Care Programs
3. Limited Clinical Evidence Versus Alternative ACTs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Mouthpiece units delivered 44.88% of 2025 revenue, maintaining leadership due to ease of sealing and broad adult suitability. Gravity-independent models are scaling fastest at 9.14% CAGR because they operate reliably regardless of patient orientation, a feature valued in home and post-operative wards. In monetary terms, this sub-segment is forecast to add USD 362 million to oscillating positive expiratory pressure (OPEP) devices market size by 2031. Face-mask interfaces remain essential for paediatric and neuro-muscular cohorts that cannot sustain effective mouth closure, while bottle-type devices keep a low-cost niche where clinicians require fine pressure adjustment.

Competitive rivalry now centres on integrating sensors that verify pressure targets, collect usage data, and sync with hospital EHRs. Vendors that bundle cloud dashboards demonstrate higher formulary preference, even at price premiums, because they arm clinicians with compliance reports for payers. Consequently, gravity-dependent legacy designs are losing shelf space across tertiary centres, although they still serve budget-constrained facilities in Latin America and Africa.

COPD and asthma collectively held 55.01% of oscillating positive expiratory pressure (OPEP) devices market share in 2025, driven by guideline-backed positioning in exacerbation management. The broncho-pulmonary specialist community expects adoption to deepen as payers reward home-monitoring bundles. Bronchiectasis, with a 9.43% forecast CAGR, enjoys higher clinical urgency amid precision-medicine trends that match airway-clearance modalities to radiologic pattern and sputum phenotype.

As electronic-health-record flags prompt pulmonologists to consider OPEP earlier in bronchiectasis, manufacturers are co-funding registry studies to capture phenotype-specific outcomes. Post-operative pulmonary-complication prevention forms a secondary growth pocket as enhanced-recovery protocols require non-pharmacologic mucus clearance to shorten length of stay. Meanwhile, cystic-fibrosis demand plateaus as the patient base stabilises under CFTR modulators, yet lifelong therapy needs ensure steady volume.

Complete Report Scope:

• By Product Type
  • Face Mask PEP Devices
  • Mouthpiece PEP Devices
  • Bottle/Water-column PEP Devices
  • Gravity-Dependent OPEP Devices
  • Gravity-Independent OPEP Devices
• By Indication
  • COPD & Asthma
  • Bronchitis
  • Bronchiectasis
  • Cystic Fibrosis
  • Post-operative Pulmonary Complications
  • Others
• By End User
  • Hospitals & Clinics
  • Home-care Settings
  • Ambulatory Surgical Centers
  • Pulmonary Rehabilitation Centers
  • Others
• By Distribution Channel
  • Offline Retail
  • Online Platforms
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America kept its 38.05% leadership stake in 2025 by virtue of comprehensive insurance coverage and early adoption of connected respiratory technologies. U.S. hospitals discharge COPD patients with bundled OPEP kits that synchronise to cloud dashboards, while Canada's provincial systems reimburse devices under durable-medical-equipment lists. Still, reimbursement cuts to pulmonary-rehab programmes strain hospital budgets, nudging growth towards outpatient and home-care providers that can leverage telemonitoring codes. Mexico, propelled by universal-coverage expansion, imports cost-optimised mouthpiece units and may double its installed base by 2030.

Europe benefits from harmonised CE-mark rules and strong evidence-based culture. Germany and the United Kingdom integrate oscillating positive expiratory pressure (OPEP) devices market products into bronchiectasis pathways, while Spain and Italy accelerate procurement for home-oxygen patients. Eastern-European uptake lags because training shortages slow guideline implementation, yet EU recovery funds earmarked for digital health could hasten closing the gap. Region-wide, payer scrutiny emphasises proven cost offsets, favouring vendors armed with real-world evidence archives.

Asia-Pacific posts the fastest 8.27% CAGR, anchored by China's chronic-disease strategy that subsidises airway-clearance devices in community clinics. Japan's super-aged society values gravity-independent models that seniors can operate supine, while South Korea channels digitised national-insurance data to monitor adherence. India tightens quality norms, fostering trust among pulmonologists to switch from improvised bottle PEP to FDA-cleared imports. Australia's remote rural communities benefit from tele-health reimbursement that pairs indigenous patients with metropolitan respiratory therapists, underpinning steady adoption of connected devices.

1. Monaghan Medical / Trudell
2. ICU Medical
3. PARI Pharma
4. D-R Burton Healthcare
5. AirPhysio
6. R. Cegla
7. Philips Respironics
8. Baxter
9. Tactile Medical
10. Vyaire Medical
11. ResMed (Acapella)
12. Drive DeVilbiss Healthcare
13. Dynarex
14. Thayer Medical
15. Vortran Medical
16. Teleflex
17. Medica Holdings
18. Medtronic
19. Smiths Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support